BMS's Opdivo gets speedy ok for the EU market
This article was originally published in Scrip
Executive Summary
The EU's CHMP has granted a positive opinion to Bristol-Myers Squibb's immune-oncology agent Opdivo (nivolumab) in melanoma after an accelerated assessment.